Wan Minghui, Zhang Lei, Chen Yiming, Li Qiang, Fan Wenli, Xue Qingxia, Yan Fang, Song Weiguo
School of Pharmacy, Weifang Medical University, Weifang, China.
Front Oncol. 2019 Apr 16;9:274. doi: 10.3389/fonc.2019.00274. eCollection 2019.
Based on the structure of sanguinarine, fourteen phenanthridine derivatives were designed and synthesized in the current study. The cytotoxic activities of synthesized compounds were evaluated against five human cancer cell lines (MCF-7, PC3, Hela, A549, and HepG2 cell lines) via MTT assay. Among all the compounds tested, molecule exhibited significant cytotoxic activity against MCF-7 cells with a IC value of 0.28 μM. A following up enzymatic assay indicated that compound could inhibit the activity of DNA topoisomerase I/II. Further mechanistic studies performed in the MCF-7 cell line revealed that compound could arrest cell cycle in S phase and induce cell apoptosis via downregulation of Bcl-2 and upregulation of Bax. Collectively, a potent DNA topoisomerase inhibitor () was discovered, which exhibited potential as a candidate chemotherapeutic agent for the management of tumors in the present study.
基于血根碱的结构,本研究设计并合成了14种菲啶衍生物。通过MTT法评估合成化合物对五种人类癌细胞系(MCF-7、PC3、Hela、A549和HepG2细胞系)的细胞毒性活性。在所有测试化合物中,分子对MCF-7细胞表现出显著的细胞毒性活性,IC值为0.28μM。随后的酶学分析表明,化合物可抑制DNA拓扑异构酶I/II的活性。在MCF-7细胞系中进行的进一步机制研究表明,化合物可使细胞周期停滞于S期,并通过下调Bcl-2和上调Bax诱导细胞凋亡。总体而言,发现了一种有效的DNA拓扑异构酶抑制剂(),在本研究中其表现出作为肿瘤治疗候选化学治疗剂的潜力。